The U.S. District Court for the District of Delaware has awarded 10x Genomics a permanent injunction against GeoMx products produced by NanoString Technologies, a subsidiary of Bruker Corporation.
Bruker acquired NanoString earlier this year for $392.6 million. The injunction, which is set to take effect in January 2025, will prohibit Bruker from making, using, selling, or offering to sell the GeoMx Digital Spatial Profiler and associated instruments, reagents, and services for RNA and protein detection in the U.S.
At the request of 10x Genomics, the injunction will allow researchers who installed a GeoMx instrument prior to November 18, 2023, to purchase GeoMx reagents for use with existing GeoMx instruments for ongoing research, 10x Genomics said in a statement.
The injunction is the latest activity in ongoing patent infringement litigation in which 10x Genomics claims that NanoString's (now Bruker's) GeoMx products willfully infringed seven patents that were exclusively licensed to 10x Genomics by Prognosys. Additionally, the court affirmed the $31 million damages awarded in a November 2023 jury verdict, as well as supplemental damages and interest that will be added to the total damages when final judgment is entered, 10x Genomics said.
10x Genomics' litigation against Bruker/NanoString is also ongoing in the European Union. In May, the German Federal Patent Court ruled the German part of the patent in contention to be invalid; in July, the German court lifted an injunction that had suspended sales of NanoString's CosMx Spatial Molecular Imager products in Germany.
